17 results about "Terbinafine" patented technology

The invention relates to a radix scutellariae self-assembled nanoparticle and terbinafine co-loaded nanoparticle as well as a preparation method and application thereof, and belongs to the technical field of drug nanoparticles. The preparation method comprises the following two steps: preparing scutellaria baicalensis self-assembled nanoparticles, and preparing the scutellaria baicalensis self-assembled nanoparticles and terbinafine co-loaded nanoparticles. The co-loaded nanoparticles are prepared by the preparation method. The invention also discloses application of the co-loaded nanoparticles in treatment of dermatophytosis. The invention has the following advantages: the saturation solubility of baicalin (BCN) and terbinafine (TBF) is increased; the dissolution rate of the terbinafine (TBF) is obviously improved; the antibacterial effect of the TBF is improved; hypha growth, biomass generation and spore germination of three kinds of trichophyton of trichophyton rubrum, trichophyton mentagrophytes and microsporum canis can be inhibited.

The present invention belongs to the technical field of microbial fermentation, and discloses a method and application of a small molecule additive for increasing the squalene yield during the fermentation process of Schizochytrium, comprising the following steps: activation; transferring the obtained activated bacteria to a seed culture medium to obtain first-generation seeds; transferring to the seed culture medium for further cultivation to obtain second-generation seeds; transferring to the seed culture medium for further cultivation to obtain third-generation seeds; transferring to a fermentation culture medium containing terbinafine for fermentation culture to produce squalene. The present invention increases the squalene yield of Schizochytrium by adding small molecule substances to the Schizochytrium fermentation system. A small amount of terbinafine in a specific proportion can effectively inhibit the oxidation of squalene into sterol substances during the fermentation process of Schizochytrium, thereby reducing the consumption of squalene. Compared with the case without adding terbinafine, when adding an appropriate concentration of terbinafine, the squalene content is 2.63 times that of the control group, and the ratio of squalene to biomass is 2 times that of the control group.

The invention relates to otological formulations, methods and devices. The present invention relates to a formulation and a method for treating ear infections, in particular auricular mycosis and otitis externa, by single administration. The formulations comprise an antibiotic, an antifungal agent and an anti-inflammatory agent added to a thick ear carrier. In one embodiment, the formulation comprises a therapeutically effective amount of an active ingredient, including marbofloxacin, terbinafine and / or clotrimazole and dexamethasone.

The invention discloses an application of celecoxib or a pharmaceutical salt thereof in preparation of an antifungal drug synergist. An antifungal drug is selected from an azole antifungal drug, an allylamine antifungal drug or an echinocandin antifungal drug. The azole antifungal drug is selected from the group consisting of fluconazole, voriconazole, itraconazole, posaconazole and isavuconazole; the allylamine antifungal drug is selected from terbinafine; the echinocandin antifungal drug is selected from caspofungin. In-vivo and in-vitro experiments prove that when the celecoxib is combined with the azole antifungal drug and the allylamine antifungal drug terbinafine, a synergistic antifungal effect is shown, and when the celecoxib is combined with the echinocandin antifungal drug caspofungin, an additive effect is shown. Celecoxib and fluconazole are combined for use, so that the survival rate of fungal infected animals can be increased, and toxicity to wax moth larvae and mammalian cells is low.

The invention discloses an application method for controlling cotton verticillium wilt by utilizing terbinafine to target verticillium dahliae sterol binding protein VdPBP1, and relates to the technical field of cotton control, and the method comprises the following application steps: S1, confirming the characteristics of a terbinafine medicament; s2, formulating a terbinafine application scheme; and S3, verification and guarantee of prevention and control effects. According to the method, theoretical support is provided for precise prevention and control; the EC50 of the terbinafine is 10.8 ng / mL, the dosage of the medicament can be greatly reduced, the monovalence of the terbinafine is 30.4 yuan / g, so that the large-scale application cost is lower, the terbinafine is only combined with verticillium dahliae VdPBP1 and blocks mediated electron transfer of the verticillium dahliae VdPBP1, and the existing medicaments such as phenazino-1-carboxylic acid can inhibit histone acetylation and benomyl has wide action targets of interfering microtubulin, so that the application range of the medicament is widened. Non-target organisms are easily influenced; moreover, an ergosterol synthesis pathway is an essential pathway for fungi, and the VdERG1 is a single copy gene in verticillium dahliae, so that pathogenic bacteria are difficult to generate drug resistance through gene mutation, and prevention and control nodes widely cover the whole growth period.

The invention relates to otological formulations, methods and devices. The present invention relates to a formulation and a method for treating ear infections, in particular auricular mycosis and otitis externa, by single administration. The formulations comprise an antibiotic, an antifungal agent and an anti-inflammatory agent added to a thick ear carrier. In one embodiment, the formulation comprises a therapeutically effective amount of an active ingredient, including marbofloxacin, terbinafine and / or clotrimazole and dexamethasone.

This invention relates to a composition of ellagic acid and terbinafine and its application in the preparation of drugs for treating bladder cancer, belonging to the field of biomedical technology. To address the problem that terbinafine treatment of bladder cancer easily causes compensatory increases in SQLE expression levels, this invention provides a composition of ellagic acid and terbinafine, consisting of ellagic acid and terbinafine in a mass ratio of 5:8. This invention uses this composition in the preparation of drugs for treating bladder cancer. Terbinafine can directly inhibit SQLE enzyme activity, blocking cholesterol synthesis and inhibiting tumor growth, while ellagic acid can reduce the compensatory upregulation of SQLE expression caused by terbinafine alone. The synergistic effect of the two can reduce the metabolic side effects caused by terbinafine and the drug toxicity of ellagic acid, significantly enhancing the anti-bladder cancer effect and overcoming monotherapy resistance. This invention is based on the development of already marketed drugs, possessing the dual advantages of therapeutic enhancement and improved safety, providing a more optimized treatment plan for bladder cancer.

The invention discloses a method for preparing a Z-type isomer of terbinafine hydrochloride. The method uses tert-butyl acetylene as a starting material, converts it into 3,3-dimethyl-1-butynyl lithium through a reaction with n-butyl lithium, synthesizes an intermediate 13-hydroxy-6,6-dimethyl-1-heptene-4-yne with acrolein, and then synthesizes an intermediate 2E / Z-1-bromo-6,6-dimethyl-2-heptene-4-yne through halogenation; the intermediate 2 is condensed with N-methyl-1-naphthylmethylamine under alkaline conditions to synthesize terbinafine free base, and then salifies it with hydrogen chloride and refines it with methyl tert-butyl ether to obtain a high-purity terbinafine hydrochloride isomer (Z)-N-(6,6-dimethylheptene-2-en-4-ynyl)-N-methyl-1-naphthylmethylamine. The process route of the invention is short, the synthesis steps are relatively simple, the raw materials used in the experiment are easily available, the reaction conditions are relatively mild, the product quality is stable, the whole operation is simple and easy to implement, the prepared sample has high purity, and can be used for the preparation of terbinafine Z-isomer reference substance.

The invention relates to an ellagic acid and terbinafine composition and application thereof to preparation of a medicine for treating lung cancer, and belongs to the technical field of biological medicine. In order to solve the problem that in the prior art, when a single drug of terbinafine is used for treating lung cancer, SQLE feedback is increased, the invention provides an ellagic acid and terbinafine composition which is composed of ellagic acid and terbinafine in a mass ratio of 4: 7. The pharmaceutical composition provided by the invention is used for preparing a medicine for treating lung cancer, and the composition can inhibit SQLE in a targeted manner through dual mechanisms, block a cholesterol biosynthesis pathway and inhibit tumor growth; through the synergistic effect of the terbinafine and the ellagic acid, the anti-tumor effect is remarkably improved, adverse reactions such as metabolic disorder caused by the terbinafine can be reduced, the drug toxicity of the ellagic acid is reduced, and the drug resistance is effectively prevented. The pharmaceutical composition is developed on the basis of commercially available drugs, has the dual advantages of enhancing the curative effect and improving the safety, and provides a more optimized treatment scheme for lung cancer treatment.

This invention relates to a composition of ellagic acid and terbinafine and its application in the preparation of drugs for treating lung cancer, belonging to the field of biomedical technology. To address the problem of increased SQLE feedback during terbinafine monotherapy for lung cancer in existing technologies, this invention provides a composition of ellagic acid and terbinafine, consisting of ellagic acid and terbinafine in a mass ratio of 4:7. The pharmaceutical composition provided by this invention is used to prepare drugs for treating lung cancer. This composition can target and inhibit SQLE through a dual mechanism, blocking cholesterol biosynthesis pathways and inhibiting tumor growth; the synergistic effect of the two significantly enhances the anti-tumor effect, while also reducing adverse reactions such as metabolic disorders caused by terbinafine, mitigating the drug toxicity of ellagic acid itself, and effectively preventing the development of drug resistance. This invention is based on the development of already marketed drugs, possessing the dual advantages of enhanced efficacy and improved safety, providing a more optimized treatment plan for lung cancer.

The present invention relates to a formulation and method for treating an ear infection, especially otomycosis and otitis externa, by administering a one-time only treatment comprising an antibiotic, antifungal, and an anti-inflammatory in a thick, otic carrier. In one embodiment, the formulation comprises a therapeutically effective amount of active ingredients including a marbofloxacin, terbinafine and / or clotrimazole and dexamethasone.

The present invention relates to a composition for use in the treatment of onychomycosis in a foot and / or hand of an individual, the composition comprising a polymer capable of forming nanoparticles and terbinafine, or derivative or salt thereof, wherein the nanoparticles are formed with and / or in the presence of terbinafine, or derivative or salt thereof and wherein the composition is administered topically to provide a daily dose to an affected area of the digits and / or the inter-digital spaces and / or each foot and / or hand in the range of about 100µg to about 1mg of terbinafine. The invention also relates to a combination of the composition and a liquid dispensing device for dispensing a pre-defined quantity of the composition to a user's toes and / or inter-digital spaces and / or the foot or hand.

The present invention relates to a composition for use in the treatment of a fungal infection comprising a polymer capable of forming nanoparticles and terbinafine, or derivative or salt thereof, wherein the nanoparticles are formed with and / or in the presence of terbinafine, or derivative or salt thereof, and where the composition comprises: a) a ratio of terbinafine, or derivative or salt thereof, to polymer in the range of about 1:2 to 1:4; and b) up to about 30% (v / v) alcohol. The composition is particularly suited as a topical treatment for fungal nail or skin infections. The invention also relates to methods of producing such compositions and combinations which can be used to produce said same.

The invention relates to an ellagic acid and terbinafine composition and application thereof to preparation of a medicine for treating bladder cancer, and belongs to the technical field of biological medicine. The invention provides an ellagic acid and terbinafine composition which is used for solving the problem that the compensation of SQLE expression level is easily increased when terbinafine is used for treating bladder cancer, and the ellagic acid and terbinafine composition is prepared from ellagic acid and terbinafine in a mass ratio of 5: 8. The application is used for preparing the bladder cancer treatment medicine, terbinafine can directly inhibit SQLE enzyme activity, block cholesterol synthesis and inhibit tumor growth, ellagic acid can reduce SQLE expression compensatory up-regulation caused by independent treatment of terbinafine, metabolic side effects caused by terbinafine and medicine toxicity of ellagic acid can be reduced through synergism of terbinafine and ellagic acid, and the bladder cancer treatment medicine can be used for treating bladder cancer. The bladder cancer resisting effect is obviously enhanced, and the single drug resistance is overcome. Based on the development of medicines on the market, the traditional Chinese medicine composition has the double advantages of treatment synergy and safety improvement, and a more optimized treatment scheme is provided for bladder cancer treatment.

To provide a composition for use in the treatment of onychomycosis and / or tinea pedis.SOLUTION: A composition comprises a polymer capable of forming nanoparticles and terbinafine, or derivatives or salts thereof, wherein the nanoparticles are formed with and / or in the presence of terbinafine, or derivatives or salts thereof, wherein the composition is administered topically to deliver a daily dose to an infected area in the range of about 5 μg to about 50 μg of terbinafine. The invention also relates to a combination of the composition and a liquid dispensing device for dispensing a pre-defined quantity of the composition to a user's toes and / or inter-digital spaces and / or front of the foot.SELECTED DRAWING: Figure 13

The present invention relates to a formulation and method for treating an ear infection, especially otomycosis and otitis externa, by administering a one-time only treatment comprising an antibiotic, antifungal, and an anti-inflammatory in a thick, otic carrier. In one embodiment, the formulation comprises a therapeutically effective amount of active ingredients including a marbofloxacin, terbinafine and / or clotrimazole and dexamethasone.

The invention discloses a co-loaded nanoparticle of scutellaria baicalensis self-assembled nanoparticles and terbinafine, and a preparation method and application thereof, belonging to the technical field of drug nanoparticles. The preparation method comprises two steps: preparing scutellaria baicalensis self-assembled nanoparticles and preparing co-loaded nanoparticles of scutellaria baicalensis self-assembled nanoparticles and terbinafine. The co-loaded nanoparticles prepared by the preparation method. The application of the co-loaded nanoparticles in treating dermatophytosis. The invention has the following advantages: the saturated solubility of baicalin (BCN) and terbinafine (TBF) is increased; the dissolution of terbinafine (TBF) is significantly improved; the antibacterial effect of TBF is improved; and the hyphae growth, biomass production and spore germination of three dermatophytes, namely, Trichophyton rubrum, Trichophyton mentagrophytes and Microsporum canis, can be inhibited.